OTCMKTS:CRXM Gene Biotherapeutics (CRXM) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$1,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Gene Biotherapeutics alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. About Gene Biotherapeutics Stock (OTCMKTS:CRXM)Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.Read More Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. CRXM Stock News HeadlinesSeptember 16 at 2:30 AM | msn.comInaugural 'Democracy at Risk' film festival to open at Gene Siskel Film CenterSeptember 15 at 10:02 AM | msn.comKiss icon Gene Simmons gives new Linkin Park lineup his backingSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.September 15 at 10:02 AM | msn.comThe Chevrolet Styleline Driven by Gene Hackman: A Ride Based on True EventsSeptember 15 at 10:02 AM | msn.comThe Car That Starred in Gene Hackman's Most Glorious MomentSeptember 15 at 10:02 AM | mirror.co.ukKiss' Gene Simmons reveals what it was like meeting wife at X-rated Playboy mansionSeptember 14 at 4:24 AM | msn.comInvestigation will ‘expose’ Biden-Harris admin over migrant crisis: AFL’s Gene HamiltonSeptember 13 at 3:33 AM | msn.comMan killed in head-on crash on Gene Snyder identifiedSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.September 12, 2024 | msn.comPalm Springs closes Gene Autry Trail at wash for blowing sandSeptember 11, 2024 | msn.comLiam Gallagher's son Gene to open for Oasis on tour - reportSeptember 11, 2024 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)September 11, 2024 | msn.comGene Snyder Freeway crash leaves 1 dead, 3 in hospital due to wrong-way driverSeptember 11, 2024 | mirror.co.ukLiam Gallagher's son Gene, 23, 'set to support Oasis on tour' after huge role in reunionSeptember 11, 2024 | msn.com1 dead, 3 in critical condition after wrong-way crash on Gene Snyder FreewaySeptember 10, 2024 | finance.yahoo.comGene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%September 9, 2024 | msn.comApple Intelligence's Siri feature will change how we use our phones, says Deepwater's Gene MunsterSeptember 8, 2024 | bbc.co.ukSunday with Steven Rainey - Gene Moran, US national security advisor on how history may come to judge Joe Biden. - BBC SoundsSee More Headlines Receive CRXM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gene Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CRXM Previous SymbolNYSE:CXM CUSIPN/A CIK772320 Webwww.cardiumthx.com Phone(858) 414-1477Fax858-436-1001Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares14,490,000Free FloatN/AMarket Cap$1,000.00 OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Christopher J. Reinhard (Age 70)Co-Founder, CEO, President, Treasurer & Director Comp: $240kMr. James L. Grainer (Age 69)Chairman, CFO & Secretary Dr. Lois A. Chandler (Age 66)Chief Operating Officer Dr. Ronald J. Shebuski (Age 71)Chief Scientific Officer Mr. Duane LinstromGeneral CounselKey CompetitorsCornwall ResourcesOTCMKTS:CORCEloxx PharmaceuticalsNASDAQ:ELOXAdvanced Life SciencesOTCMKTS:ADLSAVAX TechnologiesOTCMKTS:AVXTClarus TherapeuticsOTCMKTS:CRXTQView All Competitors CRXM Stock Analysis - Frequently Asked Questions How do I buy shares of Gene Biotherapeutics? Shares of CRXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Gene Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gene Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO) and Adaptimmune Therapeutics (ADAP). This page (OTCMKTS:CRXM) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gene Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gene Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.